New Possibilities to Reduce the Residual Risk in Patients with Ischemic Heart Disease
https://doi.org/10.18087/cardio.2020.11.n1370
Abstract
Despite a significant progress of the recent decades, incidence of cardiovascular complications in patients with manifest, stable ischemic heart disease (IHD) is still high. Furthermore, this patient group is heterogenous; individuals with a higher risk of cardiovascular complications can be isolated from this group based on the presence of comorbidities and acute IHD on the background of the therapy. Such patients require a more aggressive treatment to influence major components of the increased risk. Even after administration of an optimum therapy, the risk for complications in such patients remains high (residual risk). The article discusses the lipid, inflammatory, and thrombotic components of residual risk in IHD patients and possibilities of their control with drugs with a special focus on possibilities of pharmaceutical correction of the risk thrombotic component in IHD patients with diabetes mellitus.
Supporting agencies: The publication was supported by AO Bayer. PP-XAR-RU-0648-1.
About the Author
L. L. Bershtein
North Western State Medical Universtiy n.a. I.I. Mechnikov, St-Peterburg
Russian Federation
Department of Hospital Therapy and Cardiology, Professor
Russian Federation
Department of Hospital Therapy and Cardiology, Professor
References
1. Mach F, Baigent C, Catapano AL, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS). Eur Heart J 2020;41(1):111. doi: 10.1093/eurheartj/ehz455.
2. Jellinger PS, Handelsman Y, Rosenblit PD, et al. American Association of Clinical Endocrinologists and American College of Endocrinology Guidelines for management of dyslipidemia and prevention of cardiovascular disease. Endocr Pract. 2017;23(Suppl 2):1-87. doi:10.4158/EP171764.APPGL
3. Expert Committee, Sergienko I.V.,Shestakova M.V.,Boitsov S.A., et al. Extreme risk category in the stratification of cardiovascular complications. Consensus council of experts. Pharmateca 2019; 26(4):138-143. Russian.
4. Kukharchuk V.V. On the extreme risk of cardiovascular diseases. Atherosclerosis and dyslipidemias 2018;4 (33):5-7. Russian.
5. Gallone G, Baldetti L, Pagnesi M, et al. Medical Therapy for Long-Term Prevention of Atherothrombosis Following an Acute Coronary Syndrome: JACC State-of-the-Art Review. J Am Coll Cardiol. 2018;72(23 Pt A):2886-2903. doi:10.1016/j.jacc.2018.09.052
6. Rallidis LS, Kiouri E, Katsimardos A, Kotakos C. Extreme-risk category: High prevalence among stable coronary patients and an emerging widening treatment gap in achieving LDL-cholesterol less than 55 mg/dL. Atherosclerosis. 2018;275:262-264. doi:10.1016/j.atherosclerosis.2018.06.821
7. Wójcik C. Emerging lipid lowering agents targeting LDL cholesterol [published online ahead of print, 2020 Apr 3]. Postgrad Med. 2020;10.1080/00325481.2020.1751422. doi:10.1080/00325481.2020.1751422
8. D.J. Maron, J.S. Hochman, H.R. Reynolds, et al. Initial invasive or conservative strategy for stable coronary disease. N Engl J Med. 2020 Mar 30. DOI: 10.1056/NEJMoa1915922
9. Bershtein L., Zbyshevskaya E.V., Katamadze N.O., et al. ISCHEMIA - the largest ever randomized study in stable coronary artery disease. Baseline characteristics of enrolled patients in one Russian site. Kardiologiia 2017;57(10):12-19. Russian.
10. Sabatine MS, Giugliano RP, Keech AC, et al. Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease. N Engl J Med. 2017;376(18):1713-1722. doi:10.1056/NEJMoa1615664
11. Giugliano RP, Pedersen TR, Park JG, et al. Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the FOURIER trial. Lancet. 2017;390(10106):1962-1971. doi:10.1016/S0140-6736(17)32290-0
12. Sim JJ, Shi J, Kovesdy CP, et al. Impact of achieved blood pressures on mortality risk and end-stage renal disease among a large, diverse hypertension population. J Am Coll Cardiol. 2014;64(6):588-597. doi:10.1016/j.jacc.2014.04.065
13. Abdelhafiz AH, Loo BE, Hensey N, et al. The U-shaped relationship of traditional cardiovascular risk factors and adverse outcomes in later life. Aging Dis. 2012;3(6):454.
14. Lee A, Morrison B, Isserow S, et al. The Impact of excessive endurance exercise on the heart. BCMJ 2016;58(4):203.
15. Arnold LW, Wang Z. The HbA1c and all-cause mortality relationship in patients with type 2 diabetes is J-shaped: a meta-analysis of observational studies. Rev Diabet Stud. 2014;11(2):138. doi:10.1900/RDS.2014.11.138
16. Arida A, Protogerou AD, Kitas GD, Sfikakis PP. Systemic inflammatory response and atherosclerosis: the paradigm of chronic inflammatory rheumatic diseases. Int J Mol Sci. 2018;19(7):1890. doi:10.3390/ijms19071890
17. Sun HH, Tian F. Inflammatory bowel disease and cardiovascular disease incidence and mortality: A meta-analysis. Eur J Prev Cardiol. 2018;25(15):1623. doi:10.1177/2047487318792952
18. Furman D, Campisi J, Verdin E et al. Chronic inflammation in the etiology of disease across the life span. Nat Med. 2019 December ; 25(12): 1822–1832. doi:10.1038/s41591-019-0675-0
19. Burska A. N., Sakthiswary R., Sattar N. Effects of tumor necrosis factor antagonists on insulin sensitivity/resistance in rheumatoid arthritis: a systematic review and meta-analysis. PLoS One 2015;10:e0128889. doi: 10.1371/journal.pone.0128889.
20. Ridker PM, Everett BM, Thuren T, et al. Antiinflammatory therapy with canakinumab for atherosclerotic disease. N Engl J Med. 2017;377(12):1119-1131. doi:10.1056/NEJMoa1707914
21. Munkhaugen J, Otterstad JE, Dammen T, et al. The prevalence and predictors of elevated C-reactive protein after a coronary heart disease event. Eur J Prev Cardiol. 2018;25(9):923-931. doi:10.1177/2047487318768940
22. Sehested TSG, Bjerre J, Ku S, et al. Cost-effectiveness of canakinumab for prevention of recurrent cardiovascular events. JAMA Cardiol. 2019;4(2):128-135. doi:10.1001/jamacardio.2018.4566
23. Imazio M, Andreis A, Brucato A, et al. Colchicine for acute and chronic coronary syndromes [published online ahead of print, 2020 Jul 1]. Heart. 2020;heartjnl-2020-317108. doi:10.1136/heartjnl-2020-317108
24. Knuuti J, Wijns W, Saraste A, et al. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. Eur Heart J. 2020;41(3):407-477. doi:10.1093/eurheartj/ehz425
25. Antithrombotic Trialists' (ATT) Collaboration, Baigent C, Blackwell L, et al. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet. 2009;373(9678):1849-1860. doi:10.1016/S0140-6736(09)60503-1
26. CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee. Lancet. 1996;348(9038):1329-1339. doi:10.1016/s0140-6736(96)09457-3
27. Bonaca MP, Bhatt DL, Cohen M, et al. Long-term use of ticagrelor in patients with prior myocardial infarction. N Engl J Med. 2015;372(19):1791-1800. doi:10.1056/NEJMoa1500857
28. Mehran R, Rao SV, Bhatt DL, et al. Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium. Circulation. 2011;123(23):2736-2747. doi:10.1161/CIRCULATIONAHA.110.009449
29. Yeh RW, Kereiakes DJ, Steg PG, et al. Benefits and Risks of Extended Duration Dual Antiplatelet Therapy After PCI in Patients With and Without Acute Myocardial Infarction. J Am Coll Cardiol. 2015;65(20):2211-2221. doi:10.1016/j.jacc.2015.03.003
30. Mauri L, Kereiakes DJ, Yeh RW, et al. Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents. N Engl J Med. 2014;371(23):2155-2166. doi:10.1056/NEJMoa1409312
31. GUSTO investigators. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med. 1993;329(10):673-682. doi:10.1056/NEJM199309023291001
32. Eikelboom JW, Connolly SJ, Bosch J, et al. Rivaroxaban with or without aspirin in stable cardiovascular disease. N Engl J Med. 2017;377(14):1319-1330. doi:10.1056/NEJMoa1709118
33. Schulman S, Kearon C; Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost. 2005;3(4):692-694. doi:10.1111/j.1538-7836.2005.01204.x
34. Liu H, Yu J, Chen F, Li J, Hu D. Inpatients with coronary heart disease have a high prevalence of chronic kidney disease based on estimated glomerular filtration rate (eGFR) in China. Heart Vessels. 2007;22(4):223-228. doi:10.1007/s00380-006-0964-7
35. Kownator S, Cambou JP, Cacoub P, et al. Prevalence of unknown peripheral arterial disease in patients with coronary artery disease: data in primary care from the IPSILON study. Arch Cardiovasc Dis. 2009;102(8-9):625-631. doi:10.1016/j.acvd.2009.05.004
36. Bhatt DL, Eikelboom JW, Connolly SJ, et al. Role of combination antiplatelet and anticoagulation therapy in diabetes mellitus and cardiovascular disease: Insights from the COMPASS Trial. Circulation. 2020;141(23):1841-1854. doi:10.1161/CIRCULATIONAHA.120.046448
Review
For citations:
Bershtein L.L. New Possibilities to Reduce the Residual Risk in Patients with Ischemic Heart Disease. Kardiologiia. 2020;60(11):110–116. (In Russ.) https://doi.org/10.18087/cardio.2020.11.n1370
Views:
1456
Email this article 
Post a Comment 
